Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.66USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$126.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,425,521
52-wk High
$148.32
52-wk Low
$121.35

Latest Key Developments (Source: Significant Developments)

J&J Vision Announced Acuvue Oasys With Transitions Light Intelligent Technology Contact Lens
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Johnson & Johnson ::ANNOUNCED ACUVUE OASYS WITH TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY CONTACT LENS.  Full Article

J&J says $12 bln of overseas cash "will come back immediately"
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Johnson & Johnson ::SAYS DOES NOT EXPECT TO SEE GENERIC COMPETITION FOR ZYTIGA IN 2018.CFO SAYS $12 BILLION OF OVERSEAS CASH "WILL COME BACK IMMEDIATELY".CFO SAYS COMPANY WILL USE REPATRIATED CASH TO FUND U.S. OPERATIONS, PAYING DOWN DEBT.CEO SAYS COMPANY IS ACTIVELY LOOKING AT STRATEGIC OPTIONS FOR DIABETES BUSINESS.  Full Article

Johnson & Johnson Reports 2017 Q4 Loss Of $3.99 Per Share
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Johnson & Johnson ::REPORTS 2017 FOURTH-QUARTER RESULTS:.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.00 TO $8.20.SEES FY 2018 SALES $80.6 BILLION TO $81.4 BILLION.SEES FY 2018 SALES UP 3.5 TO 4.5 PERCENT.J&J - 2017 FOURTH-QUARTER SALES OF $20.2 BILLION INCREASED 11.5%; EPS WAS A LOSS OF $3.99.Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S.J&J - ADJUSTED 2017 FOURTH-QUARTER EPS WAS $1.74.J&J - ‍​ COMPANY RECORDS SPECIAL ITEM CHARGE OF APPROXIMATELY $13.6 BILLION RELATED TO RECENTLY ENACTED TAX LEGISLATION.J&J - EXCLUDING NET IMPACT OF ACQUISITIONS AND DIVESTITURES, ON OPERATIONAL BASIS, WORLDWIDE SALES FOR Q4 INCREASED 4.2%.Q4 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $20.07 BILLION -- THOMSON REUTERS I/B/E/S.J&J - QTRLY WORLDWIDE CONSUMER SALES OF $3,540 MILLION VERSUS $3,432 MILLION.J&J QTRLY WORLDWIDE VELCADE SALES $271 MILLION VERSUS $273 MILLION IN Q3 2017.J&J - QTRLY WORLDWIDE PHARMACEUTICAL SALES OF $9,681 MILLION VERSUS $8,232 MILLION.J&J - EXCLUDING NET IMPACT OF ACQUISITIONS, DIVESTITURES, ON OPERATIONAL BASIS, DOMESTIC SALES ROSE 4.1% AND INTERNATIONAL SALES ROSE 4.3% IN QUARTER.FY2018 EARNINGS PER SHARE VIEW $7.87, REVENUE VIEW $80.70 BILLION -- THOMSON REUTERS I/B/E/S.J&J QTRLY WORLDWIDE ZYTIGA SALES $755 MILLION VERSUS $669 MILLION IN Q3 2017.J&J - QTRLY WORLDWIDE MEDICAL DEVICES SALES OF $6,974 MILLION VERSUS $6,442 MILLION.J&J QTRLY WORLDWIDE REMICADE SALES $1,466 MILLION VERSUS $1,647 MILLION IN Q3.  Full Article

BTG says Zytiga royalties guidance unchanged after patent setback
Wednesday, 17 Jan 2018 

Jan 18 (Reuters) - BTG ::SPOKESMAN SAYS PREVIOUS GUIDANCE ON ZYTIGA ROYALTIES IS UNCHANGED, DESPITE U.S. ADMINISTRATIVE COURT DECISION TO INVALIDATE PATENT.BELIEVES EARLIEST LIKELY U.S. GENERIC ENTRY WOULD BE OCTOBER 2018, WHICH IS ALREADY REFLECTED IN THE CONSENSUS OF ANALYSTS.  Full Article

Novartis says data reinforces ‍Cosentyx effectiveness
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Novartis AG ::NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS.‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​.‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Landmark Schizophrenia Data Receive FDA Approval For Inclusion In Invega Sustenna (Paliperidone Palmitate) Label
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Johnson & Johnson ::LANDMARK SCHIZOPHRENIA DATA THAT BRING HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVE FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA® (PALIPERIDONE PALMITATE) LABEL.JANSSEN PHARMACEUTICALS SAYS INVEGA SUSTENNA IS THE FIRST ANTIPSYCHOTIC TO HAVE U.S. FDA APPROVE INCLUSION OF REAL-WORLD DATA IN ITS PRODUCT LABELING.  Full Article

FDA Issues Class I Recall Of Reprocessed Agilis Steerable Introducer Sheath By Sterilmed
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - U.S. Food And Drug Administration::U.S. FOOD AND DRUG ADMINISTRATION SAYS ISSUES CLASS I RECALL OF THE REPROCESSED AGILIS STEERABLE INTRODUCER SHEATH BY STERILMED.U.S. FDA SAYS THE AGILIS STEERABLE INTRODUCER SHEATH’S HEMOSTATIC VALVE MAY FAIL DUE TO AN IMPROPER SEAL OF THE SHEATH HUB.U.S. FDA SAYS USE OF THE AFFECTED PRODUCTS BY STERILMED MAY CAUSE "SERIOUS HEALTH CONSEQUENCES" FOR PATIENTS, INCLUDING DEATH.  Full Article

Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS.SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS' ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425.SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT.SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​.  Full Article

FEATURE-British businesses embrace profits with a purpose

LONDON, April 23 (Thomson Reuters Foundation) - Like many combat veterans, Steve Hammond struggled for years after returning to civilian life, battling physical injuries that made it difficult to find a job and left him contemplating suicide.